Announcement PDF Immuron CEO, Steven Lydeamore to present at AusBioInvest Melbourne, Australia, October 30, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at AusBioInvest 2023 on Monday, October 30th in the 9.40am – 10.35am session (AEST) at the Park Hyatt, Melbourne, Australia. A copy of the presentation being made at AusBioInvest 2023 is included below. This release has been authorised by the directors of Immuron Limited. - - - END - - COMPANY CONTACT: Steven Lydeamore Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com About Travelan® Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveller’s diarrhoea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletised preparation of hyperimmune bovine antibodies and other factors, which when taken with meals bind to diarrhoea-causing bacteria and prevent colonisation and the pathology associated with traveller’s diarrhoea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Traveller’s Diarrhoea, reduce the risk of minor gastrointestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Traveller’s Diarrhoea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection. About Traveller’s Diarrhoea Traveller’s Diarrhoea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with Traveller’s Diarrhoea as they may be contracted while travelling and initial symptoms are often indistinguishable. About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. For more information visit: http://www.immuron.com FORWARD-LOOKING STATEMENTS: This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. AUSBIOINVEST PRESENTATION 30 OCTOBER, 2023 S t e v e n Ly d e a m o r e - C E O NASDAQ: IMRN ASX: IMC 1 SAFE HARBOR STATEMENT C e r t a i n s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n a re fo r wa rd - l o o k i n g s t a t e m e nt s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c t a t i o n s , e s t i m a t e s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i c i p a t e s ,” “ex p e c t s ,” “ i nt e n d s ,” “ p l a n s ,” “ b e l i e v e s ,” “s e e k s ,” “e s t i m at e s ,” “g u i d a n c e ” a n d s i m i l a r ex p re s s i o n s a re i nt e n d e d t o i d e nt i f y fo r wa rd - l o ok i n g s t a t e m e nt s . A l t h o u g h I m m u ro n b e l i e v e s t h e fo r wa rd - l o o k i n g s t a t e m e nt s a re b a s e d o n re a s o n a b l e a s s u m p t i o n s , t h e y a re s u b j e c t t o c e r t a i n r i s k s a n d u n c e r t a i nt i e s , s o m e o f w h i c h a re b e y o n d I m m u ro n ’s co nt ro l , i n c l u d i n g t h o s e r i s k s o r u n c e r t a i nt i e s i n h e re nt i n t h e p ro c e s s o f b o t h d e v e l o p i n g a n d co m m e rc i a l i z i n g t e c h n o l o g y. A s a re s u l t , a c t u a l re s u l t s co u l d m a t e r i a l l y d i f fe r f ro m t h o s e ex p re s s e d o r fo re ca st e d i n t h e fo r wa rd - l o o k i n g s t a t e m e nt s . T h e fo r wa rd - l o ok i n g s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n re l a t e o n l y t o e v e nt s a s o f t h e d a t e o n w h i c h t h e s t a t e m e nt s a re m a d e . I m m u ro n w i l l n o t u n d e r t a ke a ny o b l i ga t i o n t o re l e a s e p u b l i c l y a ny re v i s i o n s o r u p d a t e s t o t h e s e fo r wa rd- l o o k i n g s t a t e m e nt s t o re f l e c t e v e nt s , c i rc u m sta n c e s o r u n a nt i c i p a t e d e v e nt s o c c u r r i n g a f t e r t h e d a t e o f t h i s p re s e nt a t i o n exc e p t a s re q u i re d by l a w o r by a ny a p p ro p r i at e re g u l a t o r y a u t h o r i t y. F Y 2 0 2 4 re s u l t s i n t h i s p re s e nt a t i o n a re s u b j e c t t o a u d i t re v i e w. 2 REVENUE GENERATING WITH STRONG PIPELINE Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Major Shareholders Financial Snapshot Units % of CSO Shares on Issue 227,798,346 Holder Total Options 14,568,559 BNY Mellon Asset Management 78,704,665 34.6 % Last Traded Price IMC: A$0.075 Management & Board 6,904,554 3.0 % 52 week High/Low IMC: A$0.105 / 0.067 IMRN: $3.21 / 1.39 Authentics Australia Pty. Ltd. 6,000,000 2.6 % Grandlodge 3,846,712 1.7 % Market Cap IMC: A$17.08m Cash & Cash Equivalents (30 June 2023) A$17.2m 3 TECHNOLOGY PLATFORM FOR GUT MEDIATED DISEASES Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to milk. This enables full development of the newborn calf in addition to immunity against several pathogens.* Immuron’s proprietary technology platform combines the natural human nutrition & health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal (“GI”) tract and can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces. STEP 1 Development of Highly Specific Vaccines STEP 2 Isolation of Hyperimmune antibody-rich bovine colostrum * Gomes et. al., NFS Journal, Volume 25, November 2021, pages 111, https://doi.org/10.1016/j.nfs.2021.10.001 STEP 3 Oral Antimicrobial therapeutics without drawbacks of antibiotics FINAL PRODUCT Toxin Neutralization + Clearance of targeted gut pathogens  Reduce occurrence and reduce/relieve diarrhoea  Reduce/relieve abdominal cramping  Reduce/relieve gastrointestinal pain  Assists repair of gastrointestinal/gut wall lining  Enhance/promote immune defence  Enhance/promote health liver function Australian Permitted indications; these statements have not been evaluated by the Food and Drug Administration (FDA) 4 STRONG PIPELINE WITH NEAR TERM MILESTONES Immuron’s Clinical Programs Compound or brand name Indication IMM-124E Travelan® Traveler’s Diarrhea ETEC challenge IMM-529 Clostridioides difficile Infection & Recurrence Phase I Phase II Phase III Market Our Partners’ Clinical Programs Compound or brand name Travelan® CampETEC Partner Phase I Phase II Phase III Market Uniformed Services University Naval Medical Research Command Further information on the clinical programs can be found on slide 8 5 Traveller’s Diarrhoea (TD) STRONG SALES GROWTH IN AT TRACTIVE MARKET Market is large and growing ~7% 3 CAGR Industry tailwinds Travel picking up significantly following COVID lockdowns Frequent 30% - 70% of travelers experience TD 4 Net Sales FY23: A$1.16 million 1QFY24: A$1.35 million 229% higher than prepandemic period 1QFY20 Net Sales FY23: A$0.64 million 1QFY24: A$0.21 million 9% lower than prepandemic period 1QFY20 Australia 12 months to July 2023 short term resident returns 77% of those in 2019 1 USA Total departures June 2023 99.4% of June 2019 2 Chief Commercial Officer has 20+ year’s experience with local and global (Asia, UK) commercial leadership roles with GSK and P&G $83m Based on US annual travel numbers and a penetration rate of 15%, the market potential is estimated at $83m 5 1. https://www.abs.gov.au/statistics/industry/tourism-and-transport/overseas-arrivals-and-departures-australia/latest-release 2. https://www.trade.gov/sites/default/files/2023-09/US-Outbound-to-World-Regions.xlsx 3. Research Reports World, 28 May 2021: Global Traveler’s Diarrhea Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2021-2027 4. Centers for Disease Control and Prevention Yellow Book 5. IMC Company Report - Travelan Market Analysis 2019 $50m Based on EU travel numbers and a penetration rate of 15%, the market potential is estimated at $50m 5 6 VALUABLE SALES POTENTIAL FOR PIPELINE PRODUCTS Lumanity* CorporateOpportunity Assessment for IMM-124E › › › › Immuron’s development of IMM-124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating > 80% protection against the development of diarrhea. If base case efficacy targets are reached, IMM-124E would mostly be used by travelers going to the highest risk areas (e.g., rural Central America/Asia/Africa). Based on the estimated market size and pricing, the base case yearly revenue in USA for IMM-124E is projected at US$102M. Reaching higher efficacy goals could broaden use. Compound or brand name Indication IMM-124E - Travelan® Traveler’s Diarrhea ETEC challenge IMM-529 Clostridioides difficile Infection & Recurrence › › Lumanity Opportunity Corporate Assessment for IMM-529 › › › Infectious disease experts reacted favorably to the IMM-529 MOA, and its unique ability to target three elements of the rCDI infection – the spores, vegetative cells, and Toxin B Non-microbiome approaches (such as IMM-529) are still appealing to experts, who noted that clinical trial efficacy (reduction in relapse rate) and cost/access will be the key drivers of clinical use in recurrent patients, not mechanism of action Based on the estimated market size, anticipated payer restrictions, pricing, and competition, base case yearly revenue in USA for IMM-529 is conservatively projected at US$93M for the target patient population (limited to 2nd recurrence and later based on trial design and payer coverage) Positioning IMM-529 earlier than second recurrence and/or efficacy targets could lead to higher uptake. Phase I Phase II Phase III Lumanity, a leading lifescience consulting company: https://lumanity.com/company/our-story/ Clostridioides difficile infections (CDI) to grow to almost $1.7 billion by 2026, according to GlobalData Market 7 NEAR TERM MILESTONES ANTICIPATED TO DRIVE VALUE 2H 2022 • Travelan® • • CampETEC IMM-529 • • Travelan® 1H 2023 2H 2023 1H 2024 • FDA IND1 approved for single daily dose IMM-124E ETEC2 CHIM3 clinical trial • • • IRB Approval4 Initiated IMM-124E ETEC2 CHIM3 • clinical trial 100% of patients enrolled Completion of In-patient phase ETEC2 CHIM3 clinical trial Submitted Response Letter to FDA Clinical Hold Immuron sponsored Toxicology study - completed • • • Toxicology Study Report FDA IND1 approved (Clinical Hold released) Institutional Review Board approval of NMRC5 CampETEC Campylobacter CHIM3 clinical trial protocol FDA approval of IND amendment for change to protocol • • IMM-529 cGMP manufacture • • ~50% of 868 participants recruited • • 600 mg solid dose active formulation development USU6 P2TD IMM-124E field clinical trial recruitment commencement • Completed; 1. Investigational New Drug; 2. Enterotoxigenic E.coli; 3. controlled human infection model; 4. Institutional Review Board; 5. Naval Medical Research Command; 6. Uniformed Health Services University of the Health Sciences; 7. Clostridioides Difficile • • Topline results for IMM-124E ETEC2 clinical trial Clinical Study Report Initiate NMRC5 CampETEC Campylobacter CHIM3 clinical trial Completion of In-patient phase CampETEC Campylobacter CHIM3 clinical trial IMM-529 (CDI)7 Pre-IND1 submission Completion of enrollment Completion of in-patient phase 8 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +613 8892 4854 9 SCIENTIFIC REFERENCES Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up to 90% of volunteers Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 Clinical Evaluation of Travelan® an Oral Prophylactic for Prevention of Travelers’ Diarrhea in Active Duty Military Service Assigned Abroad. Military Health System Research Symposium 14-17 Aug 2023_Abstract 1 Travelan as a broad Spectrum anti-bacterial Immuron Limited, 29 April, 2011 Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of traveler’s diarrhea US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 4 September, 2019 Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals compared to placebo and demonstrated a significant clinical benefit US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 5 September, 2018 Travelan® able to bind and was reactive to 60 clinical isolates of each bacteria, Campylobacter, ETEC, and Shigella US Department of Defense, Armed Forces Research Institute of Medical Sciences (AFRIM), 30 January, 2017 Efficacy of hyperimmune bovine colostrum against shigellosis in rhesus macaque (Macaca mulatta), and bioactivity of HBC against common enteric pathogens Islam et al., 2020. Submitted to mSphere, American Society for Microbiology Bioactive Immune Components of Travelan® Clin Vaccine Immunol 24:e00186-16. https://doi.org/10.1128/CVI.00186-16 Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM-124E) has a non-detrimental effect on gut microbial communities in unchallenged mice Rachele Gore, Mitra Mohsenipour, Jennifer L Wood, Gayathri K Balasuriya, Elisa L Hill-Yardin, Ashley E Franks Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis Journal of Crohn's and Colitis, Volume 13, Issue 6, June 2019, Pages 785–797, https://doi.org/10.1093/ecco-jcc/jjy213 IMM-529 Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5 10